CANBRIDGE-B (01228) surged nearly 17% again, with cumulative gains exceeding 1,500% year-to-date. As of press time, the stock was up 14.36% to HK$2.23, with a turnover of HK$41.075 million.

On the news front, CANBRIDGE recently announced a share subscription agreement with Qingdao Baheal Medical Inc. Under the arrangement, Baheal Medical will subscribe to approximately HK$100 million worth of CANBRIDGE shares at HK$1.34 per share. Simultaneously, both companies have signed an exclusive commercialization service agreement to further deepen their strategic collaboration. According to the agreement, Baheal Medical's subsidiaries will obtain promotional rights for specific products under CANBRIDGE in mainland China, Hong Kong, and Macau.

Additionally, the National Medical Insurance Administration announced on August 12 the preliminary approval list for the commercial insurance innovative drug catalog. Three of CANBRIDGE's rare disease products successfully passed the formal review for the commercial insurance innovative drug catalog. These include Gorlinin (Velaglucerase beta for injection), a long-term enzyme replacement therapy for Gaucher disease types I and III in adolescents aged 12 and above and adults, which received marketing approval in May this year; Maireben (Chlormadibate oral solution) for treating ALGS/PFIC cholestatic pruritus; and Hairisi (Idursulfase beta injection) for treating mucopolysaccharidosis type II.